SS-31 research record explained: Endothelial Glycocalyx Degradation as a Mediator of Neuroinflammation and Cognitive Impairment in Aged Rats: P

Quick answer

For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” sS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.¹

This is a description of its mechanism of action from regulatory and laboratory sources.¹ For Filipino readers, “SS-31: Endothelial Glycocalyx Degradation as a Mediator of” is best read by matching every conclusion to the exact study, population, outcome, and product identity. The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.²

What did this SS-31 record actually examine?

For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” start with the recorded result, not the marketing version. SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.¹

Within “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding.¹ This is a description of its mechanism of action from regulatory and laboratory sources.¹

For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” that boundary keeps one result from becoming a universal promise. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” the clearest route is to separate the result from its interpretation. WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.³

Within “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” WHO guidance on suspected falsified medical products and regulatory laboratory testing.³ Appearance alone cannot authenticate a product or establish a research outcome.³

In “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” the careful reading is narrower than a social-media headline. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

The plain-language rule for “SS-31: Endothelial Glycocalyx Degradation as a Mediator of” is simple: identify what was measured before asking what it might mean elsewhere. A precise answer can still be interesting; it simply keeps the reader oriented.

Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.

What was the main finding?

For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” one precise finding is more useful than a broad slogan. In a 12-week randomized trial of 12 males with Barth syndrome, the primary endpoints included the distance walked in six minutes and a measure of muscle strength.⁴

Within “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” The FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome.⁴ The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints.⁴

That distinction gives “SS-31: Endothelial Glycocalyx Degradation as a Mediator of” a useful answer without making it sound larger than the evidence. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” the study becomes easier to read when its boundaries remain visible. A study record is most useful when its reported result remains attached to the population, design, source identifier, and exact product identity.⁵

Within “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” Editorial synthesis of the canonical research records and Philippine verification sources.⁵ This synthesis is educational and is not personal medical advice or a product recommendation.⁵

Keeping that boundary visible makes “SS-31: Endothelial Glycocalyx Degradation as a Mediator of” clearer for a general reader. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

A useful magazine explanation of “SS-31: Endothelial Glycocalyx Degradation as a Mediator of” should make the main point easy to find. It should also keep the study boundary close enough that readers do not need to hunt for it.

Which study details change the interpretation?

For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” a useful summary begins with the outcome the researchers actually recorded. In a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.⁶

Within “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it.⁶ This was an open-label study with a small number of participants, and all knew they were receiving the active drug.⁶

This is the point where “SS-31: Endothelial Glycocalyx Degradation as a Mediator of” changes from a claim into an evidence question. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

What should not be borrowed from the result?

For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” start with the recorded result, not the marketing version. The same long-term Barth syndrome study also reported improvements in three-dimensional echocardiographic measures of left ventricular stroke, end-diastolic, and end-systolic volumes.⁷

Within “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” The TAZPOWER open-label extension found that 3D left ventricular stroke, end-diastolic, and end-systolic volumes improved, showing significant trends for improvement from baseline to week 168.⁷ These are secondary endpoint findings from a small, open-label study.⁷

How does the wider evidence sharpen the picture?

For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” one precise finding is more useful than a broad slogan. The MMPOWER-3 phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints for improving the six-minute walk distance or total fatigue score after 24 weeks.⁸

Within “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” The MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24.⁸ This was the overall result for a genetically diverse population.⁸

A catalog card does not change the evidence boundary in “SS-31: Endothelial Glycocalyx Degradation as a Mediator of”.⁵ It helps readers locate a live item while the article keeps scientific and product questions separate.⁵

Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

What should Filipino readers verify next?

For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” a useful summary begins with the outcome the researchers actually recorded. The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.²

Within “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” Official Philippine regulatory verification service.² A portal record applies to the exact product or establishment named in that record.²

Bottom line

For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” the FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding.¹ This is a description of its mechanism of action from regulatory and laboratory sources.¹

The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.² For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” this check belongs beside the science rather than underneath it.

For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” the sound conclusion keeps the source, study context, and product identity separate.

Frequently asked questions

What is the fastest way to understand SS-31?

SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.¹ For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” begin there, then keep the study setting and stated limit beside the result instead of jumping to a broader conclusion.

Does one positive finding settle the whole topic?

No. The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints.⁴ In “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” a finding can be useful while remaining narrow, early, or tied to one measured outcome.

Why does the study context matter?

The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it.⁶ For “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” changing the population, design, formulation, or outcome changes the question being answered.

What should Filipino readers verify?

The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.² While reading “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” check the exact product and establishment details rather than relying on a familiar molecule name.

Do the SS-31 and MOTS-C cards prove a benefit?

No. In “SS-31: Endothelial Glycocalyx Degradation as a Mediator of,” they are live catalog references for navigation. They do not turn a study result into a product claim, prove equivalence, or suggest using the items together.⁵

Sources

Footnotes

1. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.. The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding. This is a description of its mechanism of action from regulatory and laboratory sources. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

2. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

3. WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩² ↩³

4. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE). The FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome. The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints. ↩ ↩² ↩³ ↩⁴

5. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.; Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

6. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it. This was an open-label study with a small number of participants, and all knew they were receiving the active drug. ↩ ↩² ↩³ ↩⁴

7. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. The TAZPOWER open-label extension found that 3D left ventricular stroke, end-diastolic, and end-systolic volumes improved, showing significant trends for improvement from baseline to week 168. These are secondary endpoint findings from a small, open-label study. ↩ ↩² ↩³

8. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.. The MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24. This was the overall result for a genetically diverse population. ↩ ↩² ↩³